Feds broaden insider trading probe at FDA; Pfizer sues Watson to blog Viagra copy;

@FiercePharma: ASCO spotlight on Yervoy, Zytiga and more. Story | Follow @FiercePharma

> A federal inquiry into insider trading at the FDA is being widened to look at other government employees, the Wall Street Journal reported, citing people familiar with the matter. News | Report

> Watson Pharmaceuticals said Pfizer is suing to prevent the generic drug maker from selling a knock-off version of Viagra. Article

> Mylan won FDA approval for a generic version of Pfizer's antidepressant Effexor XR, which it will sell under an agreement with Pfizer's Wyeth unit. Story

> Investors should be wary of global pharmaceutical stocks over the next six months, a Jefferies analyst said, because they have become overpriced. Report

> Shareholders of Biogen Idec approved measures today that will let them take advisory votes annually on executive compensation and elect the company's entire board of directors every year. News

> Drugmakers are increasingly using more sophisticated excipients and blends in order to defend against generic competition, according to new market research. Item

> Teva Pharmaceutical Industries has completed patient enrollment in a new trial of its higher dosage of Copaxone, used to treat multiple sclerosis. Report

Biotech News

@FierceBiotech: BMS, Roche join forces and drugs on combo melanoma program. Story | Follow @FierceBiotech

@JohnCFierce: Orexigen says the FDA wanted a cardio trial that is "unprecedented...generate significantly more information than is necessary or feasible." Follow @JohnCFierce

> Theratechnologies cuts staffers amid R&D makeover. Story

> BusinessWeek: Pharma's recovery "starts by admitting" biz model problem. Article 

> Globe highlights targeted cancer drugs from Pfizer, Roche ahead of ASCO. News

> Orexigen puts breaks on U.S. obesity drug development. Report

And Finally... U.S. experts are concerned that European doctors are focusing on antibiotic treatment for the E. coli outbreak, saying that the drugs can worsen complications of the infection. Report

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.